Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- WEC -0.5% (guidance)
Other news:
- MRNS -74.1% (provides update on the phase 3 raise trial and reports preliminary Q1 results)
- NMRA -14.5% (announces Clinical Hold of Phase 1 NMRA-266 Study)
- RARE -10.7% (announces new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome)
- IVVD -5.1% (announces that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code (Q0224) covering product reimbursement for PEMGARDA)
- OSUR -3.3% (reports cybersecurity incident; also reaffirms Q1 revenue guidance)
- IPHA -2% (Innate Pharma Announces Advancement of Sanofi (SNY)-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients)
- GPI -1.9% ( to acquire Inchcape U.K. Dealerships for $439 mln)
- TGTX -1.5% (announces presentation of data for BRIUMVI in multiple sclerosis at the American Academy of Neurology 2024 Annual Meeting)
- ZIP -1.4% (COO Qasim Saifee to resign, effective April 30)
- CGC -1.4% (shareholders approve the creation of a new class of Exchangeable Shares of Canopy Growth)
- TSLA -1.3% (lowers Full Self-Driving capability subscription price to $99.00 from $199.00; to eliminate more than 10% of global workforce, according to Electrek)
- BALY -0.9% (files for 7,911,724 share common stock offering by selling shareholders)
- DJT -0.9% (first auditor resigned after a few months, according to FT)